Factoring in potential fall-out from the Zantac litigations
16/08/22 -"Given the negative investor sentiment regarding the potential negative implications associated with the start of the trial (by end-Aug 2022) for heart-burn drug Zantac in the US, we have injected a ..."
Pages
73
Language
English
Published on
16/08/22
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated